Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.30 |
| ▸ | ACP1 | P24666 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975175 | 0.80 | TDP1 (0.47) | — | |
| SCHEMBL794166 | 0.74 | BACE1 (0.42) | GLANPSR1BACE1PTPN1ACP1 | |
| SCHEMBL3784327 | 0.73 | ALDH1A1 (0.46) | GLANPSR1PTPN1ACP1CDC25B | |
| SCHEMBL6385190 | 0.72 | PTPN1 (0.46) | GLANPSR1PTPN1ACP1CDC25B | |
| SCHEMBL25185948 | 0.70 | PTPN1 (0.49) | GLANPSR1PTPN1ACP1CDC25B | |
| SCHEMBL21221176 | 0.69 | NOD1 (0.35) | L3MBTL1 | |
| SCHEMBL18556773 | 0.69 | GLA (0.41) | GLANPSR1BACE1PTPN1ACP1 | |
| SCHEMBL21999082 | 0.69 | GLA (0.43) | GLANPSR1BACE1PTPN1ACP1 | |
| SCHEMBL23459024 | 0.69 | LMNA (0.39) | — | |
| SCHEMBL23459023 | 0.69 | LMNA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-11584761-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4013741-A1 | PROCESS OF MAKING CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | GLA 4641/4885NPSR1 1878/4885BACE1 3859/4885 |
| US-11584761-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | GLA 4641/4885NPSR1 1878/4885BACE1 3859/4885 |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | GLA 4641/4885NPSR1 1878/4885BACE1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.